



NOTICE OF MEETING AND AGENDA
Communication and Public Education Committee
January 31, 2018

DATE/TIME: January 31, 2018, 9:00 a.m.

PLACE: Department of Consumer Affairs
1625 N. Market Blvd., 1st Floor Hearing Room
Sacramento, CA 95834

NOTE: Pharmacists and pharmacy technicians who attend in person may be awarded two hours of continuing education credit, in accordance with the board's CE policy. Sign in and sign out on the day of the meeting will be required for CE credit.

To verify the meeting call (916) 574-7918 or (916) 574-7900, or access the board's website at www.pharmacy.ca.gov. Meeting materials should be available on the website by January 26, 2018.

Important Notices to the Public: *The meeting is open to the public and accessible to the physically disabled. A person who needs a disability-related accommodation or modification to participate in the meeting may make a request by contacting Laura Hendricks at (916) 574-7918 or laura.hendricks@dca.ca.gov, or by sending a written request to the Board of Pharmacy, 1625 N. Market Blvd., Suite N-219, Sacramento, CA 95834. Providing your request at least five business days before the meeting will help ensure availability of the requested accommodation.*

Discussion and action may be taken on any item on the agenda. The time and order of agenda items are subject to change at the discretion of the committee chairperson and may be taken out of order. In accordance with the Bagley-Keene Open Meeting Act, all meetings of the board are open to the public. In the event a quorum of the committee is unable to attend the meeting, or the committee is unable to maintain a quorum once the meeting is called to order, the members present may, at the chairperson's discretion, continue to discuss items from the agenda and to make recommendations to the committee or to the full board.

Government Code Section 11125.7 provides an opportunity for the public to address each agenda item during discussion or consideration by the committee or prior to the committee taking any action on the item. Members of the public will be provided appropriate opportunities to comment on any issues before the committee, but the committee chairperson may, at his or her discretion, apportion available time among those who wish to speak. Individuals may appear before the committee to discuss items not on the agenda; however, the committee can neither discuss nor take official action on these items at the time of the same meeting. (Government Code Sections 11125, 11125.7(a)).

Agenda

Call to Order

9:00 a.m.

1. Call to Order and Establishment of Quorum
2. Public Comment for Items Not on the Agenda; Matters for Future Meetings
Note: The committee may not discuss or take action on any matter raised during the public comment section that is not included on this agenda, except to decide to place the matter on the agenda of a future meeting. Government Code Sections 11125 & 11125.7(a).
3. Presentation by Ramón Castellblanch, Ph.D., Regarding Prescription Drug Overdose Prevention and Corresponding Responsibility
4. Discussion and Consideration of a Proposal for a Public Service Billboard Message and Related Communications Materials on Drug Abuse
5. Discussion and Consideration of Possible Options for Consumer and Pharmacist Education Regarding Safe Medication Transitions for Patients upon Discharge from Health Care Facilities and Any Necessary Statutory or Regulatory Changes
6. Discussion and Consideration of Educational Materials Regarding Drug Take-Back Collection Receptacles and Providing Public Access to Such Information
7. Discussion and Consideration of Creating Webinar Course to Satisfy Education Requirement for Pharmacists to Furnish Naloxone
8. Discussion and Consideration of UC Berkeley Study of the Availability of Contraception Prescribed by Pharmacists in California
9. Discussion and Consideration of FDA Proposal to Increase Consumer Protection from High-Risk Homeopathic Drugs
10. Discussion and Consideration of FDA Guidance, “Evaluating Drug Effects on the Ability to Operate a Motor Vehicle”
11. Discussion and Consideration of *Journal of the American Pharmacists Association* Article, “Enhancing the Educational Value of Direct-to-Consumer Advertising of Prescription Drugs”
12. Discussion and Consideration of Annual Report of the Research Advisory Panel of California
13. Discussion and Consideration of Granting Continuing Education Credit for Reading *The Script*
14. Update and Discussion of Communication and Public Education Activities by Board Staff
 - a. Communication Plan for Consumers and Licensees
 - b. The Script
 - c. News Media
 - d. Public Outreach

15. Review and Discussion of News or Journal Articles

16. Future Meeting Dates

Adjournment

Upon conclusion of business